Vivo Capital’s Sage Therapeutics SAGE Stock Holding History

Vivo Capital’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-353,511	Closed	-$21.6M	–	67
2020 Q3	$21.6M	Buy	353,511 +10,332	+3%	+$524K	1.25%	18
2020 Q2	$14.3M	Buy	+343,179	New	+$12.5M	1.02%	27

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vivo Capital's SAGE Position: Q4 2020 in Review

Vivo Capital sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 353,511 shares — an estimated $21.6M sold.

Vivo Capital first reported a position in SAGE in Q2 2020 and held it in 2 quarters. The position peaked at $21.6M in Q3 2020. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

Vivo Capital reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
Vivo Capital sold 353,511 Sage Therapeutics shares in Q4 2020, an estimated $21.6M.
Vivo Capital first reported a position in Sage Therapeutics in Q2 2020 and held it in 2 quarters.
Vivo Capital's Sage Therapeutics position peaked at $21.6M in Q3 2020.
249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Vivo Capital's 13F filing for Q4 2020, filed 16 Feb 2021.